Lepu Holdings

Lepu Biopharma is a China-based, innovation-driven oncology company focused on targeted therapies and immuno-oncology, with a particular emphasis on antibody-drug conjugates. The company has built an integrated value chain spanning discovery, clinical development, CMC, GMP manufacturing, and commercialization. Its pipeline includes commercial and clinical-stage oncology assets targeting PD-1, EGFR, tissue factor, HER2, CD20, glypican-3, cadherin-17, and Claudin 18.2, alongside an oncolytic virus program. Lepu Biopharma is listed in Hong Kong and has positioned ADCs as its core technology platform. The business appears to be the closest healthcare-related match to the requested name "Lepu Holdings," although the requested name itself is not the company's exact canonical name.